ステロイド抵抗性急性移植片対宿主病の治療のためのルキソリチニブへの臍帯血組織由来間葉系間質細胞の追加
ステロイド抵抗性急性移植片対宿主病の治療のための、ルキソリチニブ対ルキソリチニブ単独と組み合わせた臍帯血組織由来間葉系間質細胞の2用量の無作為化対照パイロット研究
This early phase I trial is to find out the effect of adding cord blood tissue-derived mesenchymal stromal cells (cb-MSCs) to ruxolitinib in treating patients with acute graft versus host disease that does not respond to steroid therapy (steroid-refractory). Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. cb-MSCs are a type of tissue helper cell that can be removed from donated umbilical cord blood tissue and grown into many different cell types that can be used to treat cancer and other disease, such as graft versus host disease. This trial aims to learn if adding cb-MSCs to ruxolitinib may help control steroid-refractory acute graft versus host disease.
調査の概要
詳細な説明
PRIMARY OBJECTIVE:
I. To estimate between-arm differences (Arm 3 versus [vs] Arm 1, and Arm 2 vs Arm 1) for each of the 28-day co-primary outcome probabilities.
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM 1: Patients receive ruxolitinib orally (PO) twice daily (BID) for at least 3 days and may consider tapering after 6 months of therapy if response occurs and therapeutic corticosteroid doses have been discontinued.
ARM 2: Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive lower dose of cb-MSCs intravenously (IV) for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.
ARM 3: Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive higher dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.
After completion of study treatment, patients are followed up on day 28 and then for up to 6 months.
研究の種類
入学 (推定)
段階
- 初期フェーズ 1
連絡先と場所
研究連絡先
- 名前:Partow Kebriaei, MD
- 電話番号:713-745-0663
- メール:pkebriae@mdanderson.org
研究場所
-
-
Texas
-
Houston、Texas、アメリカ、77030
- 募集
- M D Anderson Cancer Center
-
コンタクト:
- Partow Kebriaei, MD
- 電話番号:713-745-0663
- メール:pkebriae@mdanderson.org
-
主任研究者:
- Partow Kebriaei, MD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Participants between the ages of 12 years and 80 years (inclusive).
- Steroid refractory grades II-IV acute GVHD of the Lower GI tract or Liver (including those developing these manifestations after previous acute GVHD of skin) secondary to allogeneic HCT or donor lymphocyte infusion. (Grading, see Appendix I) GVHD with: No improvement after treatment with methylprednisolone at ≥ 2.0 mg/kg/day or equivalent for minimum 7 days, or progressive symptoms after minimum 3 days, or a flare in acute GVHD while on systemic steroids. Participants must have had a biopsy that suggests GVHD; a repeat biopsy to enroll on the study is not necessary.
- Karnofsky/Lansky Performance score of at least 30 at the time of study entry.
- Participants who are women of childbearing potential, must be non-pregnant, not breast-feeding, and use adequate contraception. Male patients must use adequate contraception
- Participants (or legal representative where appropriate) must be capable of providing written informed consent, and assent if indicated.
Exclusion Criteria:
- De novo chronic GVHD
- Isolated acute GVHD of skin
- Secondary systemic therapy for acute GVHD ruxolitinib greater than 96 hours before initiation of therapy.
- Primary treatment with agents other than alpha-1 antitrypsin (AAT) glucocorticoids and ruxolitinib.
- Participants with uncontrolled infections will be excluded. Infections are considered controlled if appropriate therapy has been instituted and, at the time of enrollment, no signs of progression are present. Progression of infection is defined as hemodynamic instability attributable to sepsis, new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.
- Adult and pediatric patients with cognitive impairments and/or any serious unstable pre-existing medical condition or psychiatric disorder that can interfere with safety or with obtaining informed consent or compliance with study procedures.
- Participants with significant supplemental oxygen requirement defined as >6 L oxygen by nasal cannula.
- Participants with known allergy to bovine or porcine products.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Arm 1 (ruxolitinib)
Patients receive ruxolitinib PO BID for at least 3 days and may consider tapering after 6 months of therapy if response occurs and therapeutic corticosteroid doses have been discontinued. |
Given PO
他の名前:
|
|
実験的:Arm 2 (ruxolitinib, lower dose ds-MSCs)
Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive lower dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses. |
Given PO
他の名前:
Given ds-MSCs IV
他の名前:
|
|
実験的:Arm 3 (ruxolitinib, higher dose ds-MSCs)
Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive higher dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses. |
Given PO
他の名前:
Given ds-MSCs IV
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
あらゆる原因による死亡
時間枠:積極的な研究治療の開始から28日以内
|
積極的な研究治療の開始から28日以内
|
|
|
有害事象の発生率
時間枠:積極的な研究治療の開始から28日以内
|
積極的な研究治療の開始から28日以内
|
|
|
Response
時間枠:At day 28 from start of therapy on study
|
Will compare the patient's 28-day graft versus host disease (GVHD) status to the patient's baseline GVHD status when steroid refractory acute GVHD was diagnosed. |
At day 28 from start of therapy on study
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
各臓器の完全奏効の発生率
時間枠:6ヶ月まで
|
6ヶ月まで
|
|
|
各臓器の非常に良好な部分反応の発生率
時間枠:6ヶ月まで
|
6ヶ月まで
|
|
|
各臓器の部分反応の発生率
時間枠:6ヶ月まで
|
6ヶ月まで
|
|
|
臓器反応の持続性
時間枠:6ヶ月まで
|
6ヶ月まで
|
|
|
非再発死亡率(NRM)の累積発生率
時間枠:治療後6ヶ月で
|
治療後6ヶ月で
|
|
|
原疾患の再発・進行の累積発生率
時間枠:6ヶ月で
|
6ヶ月で
|
|
|
全生存
時間枠:登録からあらゆる原因による死亡まで、6 か月で評価
|
登録からあらゆる原因による死亡まで、6 か月で評価
|
|
|
無病生存
時間枠:登録から何らかの原因による死亡または原疾患の再発/進行まで、6か月で評価
|
登録から何らかの原因による死亡または原疾患の再発/進行まで、6か月で評価
|
|
|
あらゆるグレードのサイトカイン放出の発生率
時間枠:-最後のMSC注入治験薬を完了してから最大28日
|
-最後のMSC注入治験薬を完了してから最大28日
|
|
|
注入毒性の発生率
時間枠:各臍帯血MSC注入から24時間以内
|
各臍帯血MSC注入から24時間以内
|
|
|
Graft versus host disease status
時間枠:At days 7, 14, 21 and 28 post treatment
|
Will assess complete response (CR), very good partial response (VGPR), partial response (PR), stable disease (SD), and progressive disease (PD). |
At days 7, 14, 21 and 28 post treatment
|
|
Proportion of response
時間枠:At days 7, 14, 21 and 28 post treatment
|
Will assess proportion of patients with CR, PR, VGPR, and no-response (NR). The event NR is defined as stable disease, mixed response, disease progression, OR initiation of additional systemic (second-line) GVHD therapies. |
At days 7, 14, 21 and 28 post treatment
|
|
Time to complete response
時間枠:Up to 6 months
|
Will be estimated by the method of Kaplan and Meier. |
Up to 6 months
|
|
Time to very good partial response
時間枠:Up to 6 months
|
Will be estimated by the method of Kaplan and Meier. |
Up to 6 months
|
|
Time to partial response
時間枠:Up to 6 months
|
Will be estimated by the method of Kaplan and Meier. |
Up to 6 months
|
|
Graft versus host disease-free survival
時間枠:At 6 months
|
Patients alive, free of active acute or chronic GVHD, and without other systemic agents (or escalation of steroids to >= 2.5 mg/kg/day of prednisone [or methylprednisolone equivalent of 2 mg/kg/day]) added for treatment of GVHD will be considered successes for this endpoint |
At 6 months
|
|
Incidence of chronic graft versus host disease
時間枠:At 6 months after first mesenchymal stromal cells (MSC) infusion
|
Chronic GVHD is defined per National Institutes of Health Consensus Criteria. Diagnosis of chronic GVHD of any severity (mild, moderate, or severe) is considered an event for this endpoint. Organ involvement and maximum severity will also be described at six months. |
At 6 months after first mesenchymal stromal cells (MSC) infusion
|
|
Incidence of systemic infections
時間枠:28 days after last study drug
|
The incidence of grade 2 to 3 systemic infections occurring from study treatment until 28 days after last study drug will be described using standard Common Terminology Criteria for Adverse Events (CTCAE) criteria. Infections will be recorded by site of disease, date of onset, and severity. |
28 days after last study drug
|
|
Incidence of toxicities
時間枠:Up to 28 days after completing last MSC infusion study drug
|
The incidence of grade 3-5 treatment-emergent adverse events (per CTCAE version 5.0) that occur through 28 days after completing last MSC infusion study drug will be described. |
Up to 28 days after completing last MSC infusion study drug
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cytokine biomarker analysis (optional)
時間枠:Up to 6 months
|
Will use cytokine biomarker assays to predict response to therapy. |
Up to 6 months
|
|
Fecal samples analysis (optional)
時間枠:Up to 6 months
|
Will use fecal samples to assess microbiome and potential predictor for response to therapy. |
Up to 6 months
|
協力者と研究者
捜査官
- 主任研究者:Partow Kebriaei, MD、M.D. Anderson Cancer Center
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 2019-1122
- 2019-1122 (その他の識別子:M D Anderson Cancer Center)
- NCI-2020-13889 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
- P01CA148600 (米国 NIH グラント/契約)
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。